Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegeneration and Synaptic Repair Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NPTX1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NPTX1 Recombinant Pentameric Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View NPTX1 Products |
| Gene Delivery | NPTX1 Promise-ORF / Lentivirus Full-length ORF for stable neuronal cell line construction. |
View NPTX1 Products |
| Benchmark Ab | Anti-NPTX1 Reference Antibody Recombinant monoclonal positive control for assay calibration. |
View NPTX1 Products |
| Validator | NPTX1 siRNA Set For specific knockdown verification and specificity controls. |
View NPTX1 Products |
| Related Target: NPTX2 | Narp (Neuronal Activity-Regulated Pentraxin) Essential for subfamily selectivity counter-screening. |
View NPTX2 Products |
| Related Target: NPTXR | Neuronal Pentraxin Receptor Critical binding partner for functional interaction assays. |
View NPTXR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pentameric Oligomerization Integrity | Size-exclusion chromatography (SEC) verified pentameric structure; theoretical MW confirmed by mass spec |
| Subfamily Selectivity (vs NPTX2/Narp) | Ortholog-specific proteins with sequence-verified distinct epitopes; HEK293 expressed for native folding |
| Cross-Species Translation (Cyno/Mouse) | Human/Mouse/Cyno ortholog proteins available with >95% purity, Endotoxin controlled |
| Functional False Positives | Sequence-verified siRNA included for target-specificity confirmation in neuronal assays |
Live NPTX1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NPTX1 therapeutics is transitioning from academic neuroscience to biopharmaceutical development, driven by its critical role in AMPA receptor clustering and synaptic maintenance. As first-generation anti-amyloid therapies establish disease-modifying precedents in Alzheimer's Disease, the next wave of R&D targets synaptic repair mechanisms to address cognitive resilience. NPTX1 pentraxin signaling represents a convergent node between excitatory synapse regulation and complement-mediated pruning, positioning it for combination therapies targeting both neurodegeneration and neuroinflammation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant Replacement | Academic Consortia, Rare Disease Biotechs | Alzheimer's Disease, Synaptopathies | Pentameric Integrity Assay (Native oligomeric state essential for function) |
| Monoclonal Antibody | Neurodegeneration-Focused Biotechs | AD, Frontotemporal Dementia | CNS Penetration Validation (Need species-cross reactive proteins for PK/PD) |
| Decoy/Trap Fusion | Oncology Immunotherapy Groups | Glioma, Solid Tumors (TME modulation) | NPTX2 Cross-Reactivity Screening (High homology requires strict selectivity) |